HIV-1 and TB co-infection skew the SARS-CoV-2 T cell response
SARS-CoV-2-specific CD4 T cell attributes, rather than magnitude, associate with disease severity, with severe disease being characterized by poor polyfunctional potential, reduced proliferation capacity and enhanced HLA-DR expression.
The Wellcome Centre for Infectious Diseases Research in Africa fosters investigator-led approaches via the overarching scientific objective of combatting infection, especially HIV-1 and tuberculosis, through clinical and laboratory research.
With the fight against COVID-19 beset with concerns around the efficacy of vaccines in the face of a mutating virus, University of Cape Town virologists have shown that the body’s T cells maintain 85% of their capacity to detect variants, continuing to mount a substantial defence to prevent severe illness, hospitalisation and death.
Results published today in The Lancet Microbe detail analysis of 10 years’ health data, showing a relationship between HIV infection and acquisition of rifampicin resistance by tuberculosis. Rifampicin is an important first-line anti-tuberculosis medication.
Ongoing adaptive evolutionary convergence of the alpha, beta and gamma variants could lead to additional variants displaying any combination of increased transmissibility, altered virulence and/or increased capacity to escape population immunity.
A recent study from the University of Cape Town (UCT) confirmed that people living with diabetes (PLWD) are at an increased risk of severe COVID‑19 (hospitalisation and mortality). The findings were published in the journal Diabetes Research and Clinical Practice.